Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

The Lancet
Feb 20, 2021 Volume 397 Number 10275 p641-766
https://www.thelancet.com/journals/lancet/issue/current

Articles
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y Logunov, and the Gam-COVID-Vac Vaccine Trial Group